Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) IBB up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for three of the biggest biotech names in the market.
Analyst Andrew Peters initiated coverage on a handful of top biotech stocks on Thursday, and he sees more positives than negatives at the moment. Here’s a rundown of what he had to say (check out Peters’ track record here).
Biogen
Peters initiated Biogen Inc BIIB 0.88% at Buy with a $315 price target. Spinraza and other new drugs will likely not offset Biogen’s declining multiple sclerosis business, but Peters says investors should consider Biogen’s impressive earnings power.
“Going forward, we believe meaningful top-line growth will be driven by the pipeline and recently approved growth products (ie Spinraza), while earnings growth will further be aided by potential margin expansion,” Peters wrote.
Gilead
Peters initiated coverage of Gilead Sciences, Inc. GILD 0.01% at Buy with a $79 price target. At its current valuation, Gilead shares are pricing in the worst-case scenario, Peters wrote. Sentiment can only get better from here, and Peters expects the valuation disconnect will be short-lived. “With virtually any strategic deal making it likely to signal a positive step in the right direction, we expect the disconnect to normalize over the next 12mos, and hence see the current value as an opportunity for investors,” he wrote.
Esperion
Peters initiated coverage of Esperion Therapeutics Inc ESPR 2.74% at Buy with a $48 price target. Esperion currently has a highly favorable risk-reward balance, and Peters sees “the totality of the data to-date as highly supportive.” The next positive catalyst for the stock will likely be preliminary ph2 triplet study data in the second half of 2017 followed by pivotal data coming in the first half of 2018.
Amgen
Peters initiated coverage of Amgen, Inc. AMGN 1.19% at Hold with a $172 price target. While Peters praised Amgen’s track record of innovation, he doesn’t see…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
